Last reviewed · How we verify
BERLIM 25/10 association
BERLIM 25/10 is a fixed-dose combination of losartan (angiotensin II receptor antagonist) and hydrochlorothiazide (thiazide diuretic) that reduces blood pressure through dual antihypertensive pathways.
BERLIM 25/10 is a fixed-dose combination of losartan (angiotensin II receptor antagonist) and hydrochlorothiazide (thiazide diuretic) that reduces blood pressure through dual antihypertensive pathways. Used for Essential hypertension.
At a glance
| Generic name | BERLIM 25/10 association |
|---|---|
| Sponsor | EMS |
| Drug class | Angiotensin II receptor antagonist + thiazide diuretic combination |
| Target | AT1 receptor (angiotensin II type 1 receptor); thiazide-sensitive sodium-chloride cotransporter |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Losartan blocks angiotensin II type 1 receptors, preventing vasoconstriction and aldosterone secretion, while hydrochlorothiazide acts as a thiazide diuretic to reduce blood volume and sodium reabsorption. The combination provides synergistic antihypertensive effects with complementary mechanisms of action.
Approved indications
- Essential hypertension
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia (losartan component)
- Hypokalemia (hydrochlorothiazide component)
- Hyperuricemia
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BERLIM 25/10 association CI brief — competitive landscape report
- BERLIM 25/10 association updates RSS · CI watch RSS
- EMS portfolio CI